This bill matters because it seeks to strike a balance between encouraging innovation in new, often life-saving, genetically targeted therapies and managing the cost of prescription drugs. If this bill passes, drug companies might be more motivated to develop highly complex gene therapies, potentially leading to new treatments for difficult diseases, because they would have a longer period to recoup their significant research and development investments before facing certain price negotiations.

However, the extended protection period could also mean that certain very expensive gene therapies remain at higher prices for an additional four years for patients and government healthcare programs like Medicare. This could increase costs for taxpayers and individuals needing these drugs, impacting healthcare budgets and potentially access if costs remain a barrier for longer. Voters should care because it impacts both the availability of future medical breakthroughs and the affordability of current cutting-edge treatments.